2016•European UrologyRequires access
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)
Francisco Cruz
Open publisher page 0 citations
Abstract
This record does not include an abstract. Use the full-text link above if available.